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CHARACTERIZATION OF TCL1-Tg:p53-/- MICE THAT RESEMBLE
HUMAN CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17PDELETION

Jinyun Liu, Ph.D.

Supervisory Professor: Peng Huang, M.D. Ph.D.

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the
United States and Europe. CLL patients with deletion of chromosome 17p, where the
tumor suppressor p53 gene is located, often develop a more aggressive disease with
poor clinical outcomes. However, the underlying mechanism remains unclear. In order
to understand the underneath mechanism in vivo, I have recently generated mice with
Eu-TCL1-Tg:p53-/- genotype and showed that these mice develop aggressive leukemia
that resembles human CLL with 17p deletion. The Eu-TCL1-Tg:p53-/- mice developed
CLL disease at 3-4 months, significantly earlier than the parental Eu-TCL1-Tg mice
that developed CLL disease at 8-12 months. Flow cytometry analysis showed that the
CD5+/IgM+ cell population appeared in the peritoneal cavity, bone marrow, and the
spleens of Eu-TCL1-Tg:p53-/- mice significantly earlier than that of the parental EuTCL1-Tg mice. Massive infiltration and accumulation of leukemia cells were found in
the spleen and peritoneal cavity of Eu-TCL1-Tg:p53-/- mice. In vitro study showed that
the leukemia cells isolated from the Eu-TCL1-Tg:p53-/- mice were more resistant to
fludarabine treatment than the leukemia cells isolated from spleens of Eu-TCL1-Tg
mice. Interestingly, TUNEL assay revealed that there was higher apoptotic cell death
found in the Eu-TCL1-Tg spleen tissue compared to the spleens of the Eu-TCL1-Tg:p53-
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/-

mice, suggesting that the loss of p53 compromises the apoptotic process in vivo, and

this might in part explain the drug resistant phenotype of CLL cells with 17p-deletion.
In the present study, we further demonstrated that the p53 deficiency in the TCL1
transgenic mice resulted in significant down-regulation of microRNAs miR-15a and
miR16-1, associated with a substantial up-regulation of Mcl-1, suggesting that the p53miR15a/16-Mcl-1 axis may play an important role in CLL pathogenesis. Interestingly,
we also found that loss of p53 resulted in a significant decrease in expression of the
miR-30 family especially miR-30d in leukemia lymphocytes from the Eu-TCL1Tg:p53-/- mice. Such down-regulation of those microRNAs and up-regulation of Mcl-1
were also found in primary leukemia cells from CLL patients with 17p deletion. To
further examine the biological significance of the decrease in the miR-30 family in
CLL, we investigated the potential involvement of EZH2 (enhancer of zeste homolog
2), a component of the Polycomb repressive complex known to be a downstream target
of miR-30d and plays a role in disease progression in several solid cancers. RT-PCR
and western blot analyses showed that both EZH2 mRNA transcript and protein levels
were significantly increased in the lymphocytes of Eu-TCL1-Tg:p53-/- mice relative to
Eu-TCL1-Tg mice. Exposure of leukemia cells isolated from Eu-TCL1-Tg:p53-/- mice
to the EZH2 inhibitor 3-deazaneplanocin (DZNep) led to induction of apoptosis,
suggesting EZH2 may play a role in promoting CLL cell survival and this may
contribute to the aggressive phenotype of CLL with loss of p53. Our study reveals that
p53-miR15a/16-Mcl-1 axis & p53-miR30-EZH2 axis may contribute to the CLL
pathogenesis, and EZH2 may be a potential target for CLL treatment.
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1. INTRODUCTION
1.1 Cellular origin(s) of chronic lymphocytic leukemia. Chronic
lymphocytic leukemia (CLL) is the most common leukemia in the Western
world and accounts for about 30% of all adult leukemia cases. CLL is a disease
of elderly people resulting from an accumulation of mature-looking neoplastic
CD5+ B lymphocytes in primary & secondary lymphoid tissues, and CLL cells
express CD19, CD23 and CD20 as well (1-3). Despite the fact that over past
years several cell types have been suggested as giving rise to CLL, the cellular
origin of CLL is still unclear (4). The belief that the cellular origin of CLL is
from follicular mantle B cells due to shared surface membrane expression of
CD5 and CD23 was challenged by the DNA sequencing result showing that
approximately 50% CLL cases have IGHV mutations, whereas follicular mantle
B cells almost have unmutated IGHVs (5, 6). Another belief that CLL clones
with either mutated or unmutated IGHVs derived from marginal zone (MZ) B
cells defined as IgMhighIgDlow cells as most CLL clones also faces difficulties
because MZ B cells are CD5-CD23-CD22+ differing from CLL cells (7, 8). A
single-cell origin of CLL was challenged by the evidence for remarkably similar
B-cell receptor (BCR) amino acid sequence and striking differences in polyantigen and autoantigen-binding activity found in some CLL clones (9). The
feature of CLL clones using either mutated or unmutated IGHV genes (M-CLL
and U-CLL) gave rise to the hypothesis that 2 subgroups of CLL originated
from distinct cell types considered as a 2-cell origin model (10, 11). However,
the 2-cell origin model exhibited difficulties resulting from gene expression
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profiling which revealed that only a relatively small number of genes have
differences between U-CLL and M-CLL , whereas there are thousands of
differences between normal B lymphocytes and either U-CLL or M-CLL (12).
Therefore difference in cellular features between U-CLL and M-CLL could be
explained by a sing-cell derivation with additional and nongenetic promoting
factors. Regarding normal counterparts of CLL, leukemogenesis is at least a
multistep process. In 2011, possibilities for single- and multiple-cell origin
models offered by some researchers partially answered the question whether a
single- or multiple normal counterparts of CLL were stimulated to evolve into
CLL (9).
1.2 Genetic abnormalities in CLL. Fluorescence in situ hybridization
(FISH) analysis has revealed that up to 80% of CLL cases exhibited
chromosomal abnormalities such as deletions of 13q14 in 55% CLL cases, 11q
deletion in 12%, 17p deletion in 8% and trisomy of chromosome 12 in 15% of
CLL cases (13, 14). Among the chromosomal abnormalities, deletions at 13q14
are the most frequent chromosomal abnormalities and present in more than half
of CLL cases. Some of the cytogenetic changes are associated with poor
prognosis and aggressive disease progression. Chromosome 17p deletion (17p-)
is the most recognized cytogenic alteration in CLL associated with aggressive
disease progression, resistance to chemotherapy, and poor clinical outcome (15).
Since the tumor suppressor p53 gene is located in human chromosome 17p (16),
it is suspected that the loss of p53 function in CLL cells with 17p- may be
responsible for the poor prognosis of this subgroup of CLL patients (17, 18).
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Initially, TP53 was considered as an oncogene. However, since 1989 it has been
found that p53 functions as a tumor suppressor and is frequently mutated in
human cancers (19-21). More than half of human tumors have a p53 deletion or
mutation (22). What is the p53 status in CLL? Mutations of TP53 are found in
4% to 37% of patients with CLL (23). Patients with fludarabine-refractory CLL
have the highest incidence of TP53 mutation (24). Interestingly, recent study
suggested that a very high concordance (over 70%) in 17p-deletion and
mutations in the remaining p53 allele (25). Furthermore, p53 dysfunction may
also arise via alternative mechanisms such as functional inactivation, which
may explain certain CLL with poor prognosis but without apparent structural
changes in p53 gene such as 17p-deletion or mutations (26). Thus, it is clear
that the loss of p53 function has profound effect on the CLL disease progress
and treatment outcomes. However, the underlying mechanisms remain to be
elucidated.
1.3 CLL microenvironment. The microenvironment, a complication of
accessory cells that within individual organs, provides growth factors, nutrients
and immune tolerance for the survival and propagation of malignant cells in
solid tumors through cell-cell contact and active molecular crosstalk (27). In
CLL, the interactions between the malignant cells and the microenvironment in
vivo provide the proliferative drive for the malignant cells through the external
signals from the microenvironment such as antigens, cytokines and cell-cell
contact. In vitro, CLL cells undergo spontaneous apoptosis, suggesting that
CLL cell survival depends on microenvironment signals (28, 29). There is
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growing evidence suggesting that CLL cells are protected from spontaneous
apoptosis and conventional drug in vitro by various stromal cells including
mesenchymal marrow stromal cells (MSCs) (30, 31), monocyte-derived
nurselike cells (NLCs) (30), and follicular dendritic cells (32) through coculture that partially mimics the CLL microenvironment. Interactions between
CLL cells and MSCs provide CLL survival and drug resistance by promoting
CLL cell migration which depends on CXCR4 and VLA-4 expression by CLL
cells (33). There are several common stromal cell lines used for protecting CLL
cells through co-culture, including human stromal cell lines HS5 & NK Tert and
mouse stromal cell line KUSA-H1. NLCs protect CLL cells from spontaneous
apoptosis and conventional drugs through secreting CXCL12 (30), CXCL13
(34), B cell-activating factor of the tumor necrosis factor (BAFF), CD31 and
plexin-B (35). T cells play several roles in CLL. In one hand, some subsets of T
cells may overcome the antitumor effect derived from other T-cell subsets and
favor disease progression. In the other hand, the significant immune deficiency,
which is typical in CLL, resulted from T-cell abnormalities (36, 37). The overall
number of circulating T cells stimulate CLL cell growth and survival by
secreting interleukin-4 (IL-4) and tumor necrosis factor- (TNF-) (27).
1.4 CLL treatment. CLL treatment includes chemotherapy with agents
such as fludarabine, chlorambucil, and bendamustine (38). Fludarabine, a purine
analog, generated a significant improvement in overall responses compared with
chlorambucil, an alkylating agent, in the CLL treatment (39). Up to 37% of
untreated patients with CLL do not respond to fludarabine treatment and up to
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76% of patients with CLL become refractory to the fludarabine treatment (40).
Fludarabine and chadribine in combination with cyclophosphamide are equally
effective for progressive CLL. However, both combinations are not effective in
patients with 17p13 deletion (41). Bendamustine agent, a cytotoxic hybrid of an
alkylating agent and a purine analog, has improved overall response rates (42).
The major issue for the purine analog therapy is lack of response in patients
with 17p- CLL. Histone deacetylase inhibitors (HDACIs) can induce acetylation
of histone and nonhistone proteins (43). The HDACI, valproate (VPA),
synergizes with purine analogues to induce apoptosis in CLL cells (44). βPhenylethyl isothiocyanate (PEITC), which is a natural compound found in
cruciferous vegetables, effectively eliminates fludarabine-resistant CLL cells
through ROS accumulation and glutathione depletion (45). It could be possible
that PEITC only or PEITC combined with other chemotherapy agents will take
a big step in the CLL treatment. Recent studies have shown that the compound
PEITC overcomes resistance to HDACI in human leukemia through redox
modulation (46). Despite the improvement of chemotherapy in CLL, relapse is
frequent. Rituximab (anti-CD20), the first approved therapeutic antibody in
cancer treatment, has been used in refractory CLL (47). Chemoimmunotherapy
improves overall therapy in patients with CLL and alemtuzumab (anti-CD52)
based chemoimmnotheray has improved responses in relapsed/refractory
disease (38, 48). Recently protein kinases have been considered as therapeutic
targets in CLL due to the fact that an imbalanced functional response of the Bcell receptor (BCR) signaling axis results in the deregulation of gene expression
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in CLL. Spleen tyrosine kinase (SYK) is critical for B-cell development and is
essential for the survival and maintenance of malignant B cells (49, 50). SYK
inhibition in human CLL cells led to the downregulation of Erk, Akt, and Mcl-1,
demonstrating that SYK regulates CLL survival (51-53). Bruton tyrosine kinase
(BTK) plays an essential role in B-cell signaling and development. BTK are
overexpressed in CLL lymphocytes as compared with normal B lymphocytes at
both protein and mRNA levels (54). Ibrutinib, a specific inhibitor of BTK, can
disrupt tumor microenvironment interactions, inhibit cellular migration and
adhesion and induce apoptosis in malignant B-cells (55). Despite those
significant improvements and potential therapeutic strategies in clinic, CLL still
remains an incurable disease. Novel therapeutic agents targeting different
signaling pathways will bring a new way for the future treatment of CLL and
fludarabine-resistant/refractory CLL.
1.5 Treatment resistance in CLL-the role of the p53 pathway. Despite
the improvements of chemotherapy strategies by novel therapeutic agents or
their combinations in the CLL treatment, relapse is frequent. The appearance of
effective first-line chemoimmunotherapy such as retuximab in CLL improved
the response rates for treatment-refractory patients. Genetic abnormalities such
as 13q14 deletion, un-mutated IGHV gene status, 11q deletion, particularly 17p
deletion seem to be more important in determining the treatment outcome than
initial treatment choice (56-58). CLL patients with 17p deletion have been
shown to poorly respond to conventional chemotherapies such as fludarabine
(57), probably because that the remaining allele contains a TP53 mutation or
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deletion in the most cases. Are CLL patients with TP53 mutation in the absence
of 17p deletion resistant to chemotherapy? The answer is positive. TP53
mutation

without

17p

deletion

corresponds

to

the

development

of

chemotherapy-resistant disease and is associated with poor survival (59). More
than half of human tumors have a p53 deletion or mutation (22). Mutations of
TP53 are found in 4% to 37% of patients with CLL (23). Patients with
fludarabine-refractory CLL have the highest incidence of TP53 mutation (24).
Taking together, p53 seems to play a central role in the drug resistance of CLL.
1.6 Animal models that resemble human CLL and underlying
mechanisms. Animal model tools are important to investigate disease processes
and associated pathological mechanisms in vivo. Currently there are several
CLL mouse models, which include the Eµ-TCL1 transgenic (TCL1-Tg) mice
(60), the April transgenic mice (61), the TRAF2DN/bcl2 transgenic mice (62),
the miR-155 mouse model (63), the NZB mouse model with miR-16 alteration
(64), and the miR-29 transgenic mice (65), and so on. The TCL1-Tg mouse
model, which was created by the insertion of the human TCL1 gene under the
control of the immunoglobulin heavy chain variable region promoter and
immunoglobulin heavy chain enhancer, represents a well characterized mouse
model that develops leukemia resembling human CLL (60). Why TCL1 causes
leukemia? TCL1 physically interacts with Akt through PH domain of Akt. This
interaction enhances Akt kinase activity and promotes Akt nuclear translocation
(66). It has been reported that transgenic mice expressing constitutively
activated Akt in T cells develop T cell leukemia (67), whereas transgenic mice
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expressed constitutively activated Akt in B cells do not develop B cell leukemia
(68). Those reports suggest that Akt activation causes leukemia in T cells
initiated by TCL1. However TCL1 deregulation in B cells causes CLL not
through Akt activation. Overexpression of TCL1 in B cells causes CLL by
enhancing NF-ĸB activity and inhibiting AP-1 (69). The TCL1-Tg mice develop
human CLL-like disease at 8 to 12 months of age and exhibit features of human
CLL with expanded IgM+CD5+ CLL population in peritoneal cavity (PC),
spleen and bone marrow (60). The CLL cells isolated from TCL1-Tg mice
undergo rapid cell turnover with high levels of proliferation and apoptosis (70).
TCL1XBAFF-Tg mice generated by crossing TCL1-Tg with BAFF-Tg mice,
which express high levels of CD257, develop CLL-like disease around 4.5
months of age with more rapid disease progression and shorter survival that
TCL1-Tg mice (70). BAFF and APRIL are recent members of TNF superfamily
and show increased expression levels in various B cell malignancies. BAFF and
APRIL bind to two receptors BCMA & TACI and stimulate NFĸB pathway
through interactions with TRAFs, contributing to CLL pathogenesis in
TCL1XBAFF-Tg mice and April transgenic mice (71). APRIL transgenic mice
had increased white blood cell count and did not develop any hematopoietic
malignancy probably due to lack of second hit such as TCL1 overexpression
(61). It has been reported that miR-29 is upregulated in indolent human CLL
with low ZAP-70 expression and mutated IGHV (72). MicroRNAs are
regulatory non-coding RNAs with 20 to 25 nucleotides in length. The primary
function of microRNAs is to target specific messenger RNA for degradation or
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inhibition of translation, leading to downregulation of the target proteins (73,
74). Recent studies have shown that the regulatory functions of microRNAs are
involved in various cellular processes including development, differentiation,
apoptosis, survival and metabolism (75, 76). It has been reported that
microRNA signatures are associated with CLL progression and prognosis (77,
78). Desregulation of some microRNAs have been viewed as a contributing
factor for CLL apoptotic defect. For example, upregulated Bcl-2 resulted from
downregulation of miR15a/16-1 (79). In 2006, Dr. Croce’s group reported that
Eµ-miR155 transgenic mice develop a B cell malignancy with a preleukemic
pre-B cell proliferation (63). In 2010, Dr. Croce’s group also reported that EµmiR-29 transgenic mice develop a disease that resembles human indolent CLL
phenotype probably through targeting TCL1 and Mcl-1 by miR-29 (80, 81).
Previous studies have shown that over-expression of Bcl-2 family members
occur in many cases of CLL and this is correlated with resistance to therapy and
a poor prognosis (82). A constitutive increase of Bcl-2 through a deletion of
miR-15a/16-1 cluster contributes to CLL pathogenesis (62). Bcl-2 transgenic
mice showed polyclonal expansion of B cells and increased cell survival
without developing any tumor (83). In contrast, most of TRAF2DN/Bcl2 double
transgenic mice develop B cell leukemia resembling human CLL with severe
splenomegaly and significant high number of white blood cells (62).

As

mentioned before, TRAF2, a TNF receptor associated factor 2, interacts with
TNF receptor family members such as BCMA and activates NF-ĸB and JNK
signaling pathways (84). Although Bcl-2 or TRAF2 single transgenic mice
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failed to develop any hematological malignancy, the TRAF2DN/Bcl2 double
transgenic mice had rapid disease progression and developed human CLL-like
disease over time and died at 6 to 14 months of age. NF-ĸB activation and
overexpression of anti-apoptotic Bcl-2 could contribute to the disease
progression in the TRAF2DN/Bcl2 double transgenic mice. Among the antiapoptotic members of Bcl-2 family, the myeloid cell leukemia-1 (Mcl-1) has
been demonstrated as an important anti-apoptotic protein in CLL both in vitro
and in vivo (85). It has been shown that Mcl-1 promotes CLL cell survival by
inhibiting the intrinsic Bak/Bax-mediated apoptotic pathway (86). Loss of p53
function in cancer cells has also been associated with decrease in apoptotic
response and drug resistance (59), and mice with p53-/- genotype are highly
susceptible to the development of a variety of tumors (87). However, currently
it is unclear if there is a link between the loss of p53 and over-expression of
Mcl-1 in CLL cells. As mentioned before, there is no doubt that the loss of p53
function has profound effect on the CLL disease progress and treatment
outcomes. However, there is no any animal model available for studying the
effect of p53 deletion in CLL biology and pathogenesis. TCL1-Tg mouse model
closely recapitulates human CLL disease. This mouse model can not be used to
study CLL with p53 gene deletion. To generate an animal model that closely
resembles human CLL patients with p53 deletion, we generated a mouse colony
with TCL1 transgenic and p53-deletion (TCL1-Tg:p53-/-) genotype by crossing
the TCL1-Tg mice with p53-/- mice. We hypothesized that loss of p53 causes
rapid disease progression, treatment resistance and shorter survival time in
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TCL1-Tg mice by modulating CLL cell proliferation and apoptosis. Our
preliminary data showed that the TCL1-Tg:p53-/- mice develop leukemia that
resembles human aggressive CLL disease around 3-4 months. The leukemia
cells from TCL1-Tg:p53-/- mice exhibited higher proliferation, higher survival
capacity, and more resistant to drug treatment with fludarabine than the
leukemia cells from the TCL1 transgenic mice with wild-type p53. We further
demonstrated that the loss of p53 led to a significant increase of Mcl-1
expression, likely through the expression of miR-15a and miR-16-1 expression.
Our microRNA array data showed significant downregulation of miR15a/16-1,
miR-30a, miR-30d and miR-30e, especially miR-30d, in both human and mouse
CLL cells with p53 deficiency, and such downregulation of those microRNAs
were confirmed by RT-PCR. As mentioned before, mir-15a and miR-16-1,
located at 13q14, were deleted or downregulated in approximately 66% CLL
cases (88). Recent studies have shown that the miR15a/16-1 cluster function as
tumor suppressor by targeting Bcl-2, Mcl-1, CCND1 and WNT3A (89). The
association between the loss of p53, the decrease in miR15a/16-1 and the
increase in Mcl-1 was further confirmed in primary leukemia cells from CLL
patients with chromosome 17p deletion. The role of miR30 family in CLL is
still unknown. It has been reported that miR-30d targets the polycomb protein
enhancer of zeste 2 (EZH2) which is involved in repressing gene expression
through methylation of histone H3 on lysine 27 and upregulated in anaplastic
thyroid carcinomas (90). Over years, many studies have established that EZH2
is overexpressed in various cancers including some hematologic malignancies,
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and such overexpression is associated with aggressiveness and progression (91,
92). DZNep, an S-adenosylhomocysteine hydrolase inhibitor, induce apoptosis
in cancer cells such as AML through inhibiting S-adenosyl-L-methioninedependent methyltransferases such as EZH2 (93). A recent report showed a
therapeutic strategy for lymphoma with EZH2-activating mutations through
EZH2 inhibition (94). The role of EZH2 in CLL has yet to be examined in vitro
and in vivo. Another target of miR-30 is B-Myb, which expression can be
regulated by miR-30 and miR-29 during cellular senescence (95). B-Myb, a
transcription factor, is involved in cell proliferation and transcription and
carcinogenesis. B-Myb overexpression presents in various cancers and is
associated with aggressive tumor growth and poor outcomes (96-98). However,
the role of B-Myb in CLL is still unknown. This study provides in vivo evidence
to support that p53miR15a/16Mcl-1 & p53miR30d EZH2 & B-Myb
axis may contribute to the pathogenesis of aggressive CLL.

2. SPECIFIC AIMS
Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in
Western countries, and the disease is very heterogeneous in disease progression
and response to drug treatment. Genetic aberrations such as chromosome
deletion or gene mutation are frequently observed in CLL (99). A subtype of
CLL with chromosome 17p deletion is associated with accelerated disease
progression, drug resistance, and poor prognosis due to loss of p53 gene (100).
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The subtype of CLL patients with 17p deletion or with TP53 mutations have
much shorter survival time than other CLL patients without 17p deletion and
TP53 mutations (101) . To develop efficient therapeutics for the CLL subtype
with 17p deletion or TP53 mutations, it is critical to understand how exactly
loss of p53 contributes to CLL disease progression and drug resistance.
MicroRNAs (miRNAs), a group of short non-coding RNA molecules, regulate
target gene expression via translational repression or transcriptional degradation
(74). Several miRNAs such as miR-15a, miR-16 and miR-34a have been
implicated in CLL pathogenesis and prognosis (102, 103). Interestingly, p53
can upregulate miR-34 gene and miR-34 overexpression in turn induces
senescence, apoptosis or cell cycle arrest by regulating proteins such as Bcl-2,
Cyclin D1, CDK4 and c-MYC etc (104). Moreover, deregulated miRNA
expression also mediates drug resistance in CLL patients with 17p deletion
(105-109). Overall, p53 and miRNAs have been closely linked in CLL
pathogenesis and prognosis. However, it remains unclear how loss of p53
affects miRNAs and alters the regulatory function of miRNAs in CLL. As
mentioned before, the TCL1-Tg mice develop human CLL-like disease at 8 to
12 months of age with expansion of IgM+/CD5+ CLL population in PC, spleen
and bone marrow (60). However, this TCL1-Tg mouse model can not be used to
study the effect of p53 deficiency in CLL pathogenesis and microRNA
deregulation. Therefore, we hypothesized that loss of p53 causes rapid disease
progression and shorter survival time in TCL1-Tg mice by modulating CLL cell
proliferation and apoptosis. To address this hypothesis, the TCL1-Tg:p53-/-

13

mouse model is generated by our group. This model is expected to be a good
research model for providing potential therapeutic strategies and novel
chemotherapies in the treatment of CLL subtype with 17p deletion, and for
studying CLL biology and pathogenesis. It is also anticipated that the proposed
studies will bring new insights into the relationship between loss of p53 and
microRNA deregulation in CLL. In the proposed studies, 3 specific aims will be
accomplished to address the hypothesis.
Specific Aim 1: Generation and characterization of TCL1-Tg:p53-/mice.
General strategy. TCL1-Tg homozygous mice (B6C3 mice) were provided
by Dr. Carlo M. Croce. They are crossed with p53-/- mice (B6C3) which were
from Jennifer Alana (a microinjection specialist in MDACC). Then the second
generation of TCL1-Tg:p53+/- mice were intercrossed to get TCL1-Tg:p53-/CLL mouse model. Afterwards, TCL1-Tg:p53-/- mice were intercrossed with
each other to obtain pure TCL1-Tg:p53-/- mice for research studies (Figure 1).
All mice were housed under conventional barrier protection in accordance with
University of Texas MD Anderson Cancer Center guidelines, and mouse
protocols were approved by University of Texas MD Anderson Cancer Center
Institutional Animal Care and Use Committee.
Validation of p53 deletion and TCL1 overexpression in TCL1-Tg:p53-/mice. Prior to any phenotypic analysis, the mice are genotyped for TCL1
transgene and p53 mutant alleles. Furthermore, to confirm the inactivation of
p53 protein expression, Western blot analysis of p53 will be performed using
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splenocytes and peritoneal cavity cells from mice with respective genotypes.
The TCL1-Tg mice don’t develop CLL disease until 13 months old, and p53-/mice may develop tumors at 6 months old. Most of TCL1-Tg:p53-/- are fertile
and we don’t expect any embryonic lethality or pup survival problem of these
mice. Indeed, we have obtained the TCL1-Tg:p53-/- mice in the laboratory.
Characterization of CLL phenotype of TCL1-Tg:p53-/- mice. The TCL1Tg mice develop CLL disease featured by CD5+ B cell accumulation in bone
marrow, spleen, and PC. To determine the percentage of CD5+ B cells at
different ages, I will isolate cells from bone marrow, spleen, and peritoneal
cavity of mice with difference genotypes at 2 month, 4months, 5 months, 7
months of age, and perform FACS analysis using anti-CD5 and anti-IgM
antibodies. Meanwhile, blood smear will be performed to monitor white blood
cell expansion in these mice at different ages. To further characterize the
phenotype of the TCL1-Tg:p53-/- mice, Hematoxylin and eosin (H&E) staining
of mouse tissues such as spleen and liver will be performed. Mouse survival
will be monitored for three groups of mice for up to 2 years and each group
contains more than 20 mice.
Specific Aim 2: Determine the effect of p53 deficiency on proliferation
and apoptosis of splenocytes and investigate underlying mechanisms.
Determine p53 deficiency on proliferation and apoptosis of splenocytes.
For years, CLL has been viewed as a tumor with low level of cell turn over.
Consistently anti-apoptotic Bcl-2 family members are overexpressed in most
CLL cases (82). Recently it was found that CLL cells from TCL1-Tg mice
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undergo rapid cell turnover that can be offset by extrinsic CD257 to favor
disease progression (70). We expect that p53 deficiency will accelerate CLL
disease progression in TCL1-Tg mice by modulating cell proliferation and
apoptosis. One of the complications of CLL is an enlarged spleen called
splenomegaly. To determine the effect of p53 deficiency on cell proliferation,
Bromodeoxyuridine (BrdU), a synthetic thymidine analog, incorporation assay
will be performed for splenocytes isolated from p53-/- mice, TCL1-Tg mice,
TCL1-Tg:p53+/- and TCL1-Tg:p53-/- mice. To further confirm the proliferation
result, Ki67 (a proliferation marker) staining of spleen isolated from different
types of mice will be performed. To determine the effect of p53 deficiency on
apoptosis of splenocytes, Annexin V/Propidium Iodide (PI) staining will be
performed for splenocytes isolated from p53-/- mice, TCL1-Tg mice, TCL1Tg:p53+/- and TCL1-Tg:p53-/- mice at 0, 24h and 72h after isolation. Terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay will be
performed on spleen tissues isolated from different types of mice to confirm the
apoptosis results obtained from the Annexin-V/PI analysis.
Investigate the mechanistic link between p53 deficiency and altered
proliferation & apoptosis rates of splenocytes. P53 functions as a
transcription factor and regulates the expression of a number of genes involved
in cell-cycle arrest, apoptosis and senescence (21, 110). P53 is either mutated
or deleted in more than 50% of human cancers and plays an tumor suppressor
role in cancer (22). However, it is unknown how loss of p53 affects altered
proliferation & apoptosis and pathogenesis in CLL. It has been reported that
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anti-apoptotic Bcl-2 family members are overexpressed in most CLL cases,
which is associated with chemotherapy resistance and poor prognosis (82).
Particularly Mcl-1 plays an important role for CLL survival in both in vitro and
in vivo (85). We first determine the expression of anti-apoptotic Bcl-2 family
members in mouse splenocytes and PC cells by Western blot analysis at protein
levels. PCR experiments will be also performed to determine the mRNA levels
of anti-apoptotic Bcl-2 family members. Both protein and mRNA levels of antiapoptotic Bcl-2 family members will also be determined in human CLL patient
samples with 17p deletion or without 17p deletion. We expect elevated
expression levels of anti-apoptotic Bcl-2 family members in CLL cells with p53
deficiency compared to CLL cells with p53 wt. How does p53 deficiency cause
alteration of anti-apoptotic Bcl-2 family members? It could be through
microRNA regulation. Several miRNAs such as miR-15a, miR-16 and miR-34a
have been implicated in CLL pathogenesis and prognosis (102, 103). However,
it remains unclear how loss of p53 affects miRNAs and alters the regulatory
function of miRNAs in CLL. To address that question, miRNA array will be
performed for both mouse and human RNA samples with p53wt or p53
deficiency. Regard the array data, RT-PCR experiments need to be performed to
confirm those miRNA alterations. Those miRNA targets observed may explain
the alteration of anti-apoptotic Bcl-2 family members in mouse and human CLL
cells with p53 deficiency. The mRNA and protein levels of other downstream
molecules of those miRNAs will be determined by Western blot analysis
respectively. To further confirm that p53 regulates those miRNAs, p53 will be
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knocked down in some B cell lines such as EBVB. Then the expression of those
miRNAs, Bcl-2 family and the downstream molecules of miRNAs will be
determined in the B cell lines with p53 knock-down. In summary, we expect
that p53 deficiency regulates some specific miRNAs which resulted in
upregulation

of

anti-apoptotic

Bcl-2

family

members,

leading

to

hyperperliferation, reduced apoptosis and rapid disease progression in TCL1-Tg
mice.
Specific Aim 3: Determine the effect of p53 deficiency on CLL
treatment response on cellular level and animal level. As mentioned in the
introduction part, CLL patients with 17 deletion or TP53 mutation are resistant
to conventional chemotherapies in the CLL treatment. To confirm that, CLL
patient samples with or without 17p deletion will be appropriately treated with
conventional chemotherapies such as fludarabine, chlorambucil and so on. 48h
later, Annexin-V/PI analysis will be performed for those treated cells to detect
apoptosis. Annexin-V/PI analysis will be also performed for similarly treated
mouse splenocytes isolated from p53-/- mice, TCL1-Tg mice, TCL1-Tg:p53+/and TCL1-Tg:p53-/- mice. We expect that both human CLL cells with 17p
deletion and mouse CLL cells with p53 deficiency are resistant to those
conventional chemotherapies. To overcome the treatment resistance of CLL
cells with p53 deficiency, a novel chemotherapy agent-NL-101 is studied in the
CLL treatment. NL-101 contains suberoylanilide hydroxamic acid (SAHA) and
Bendamustine moieties in 1:1 ration. We hypothesized that HDACI such as
SAHA can overcome the resistance of alkylating agents such as bendamustine
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by reducing CLL migration to the microenvironment and induce more DNA
damage than alkylating agents on CLL cells. Recent studies have shown that
SAHA induces apoptosis in CLL by downregulating the CXCR4 chemokine
receptor, leading to impaired migration of CLL cells (111). Human CLL cells
with 17p deletion or without 17p deletion will be treated with single agents such
as NL-101, bendamustine, chlorambucil, SAHA or their combinations for 48h,
and followed by Annexin-V/PI analysis. To investigate underlying mechanisms
of the novel agent NL-101 on CLL treatment, the expression levels of cytokines
in stromal cell lines treated with HDACI such as SAHA will be determined by
RT-PCR, and followed by Enzyme-linked immunosorbent assay (ELISA) assay.
Comet assay will be performed to determine DNA damage rate in CLL cells
treated with SAHA, bendamustine, SAHA+Bendamustine and NL-101. We
expect that HDACIs will reduce some cytokine levels such as CXCL12 secreted
in stromal cell lines. We also expect more DNA damage caused by NL-101 or
SAHA+bendamustine than single bendamustine treatment on CLL cells. PEITC
can effectively eliminate fludarabine-resistant CLL cells through ROS
accumulation and glutathione depletion (45). Therefore, we will try PEITC
treatment or combination with other chemotherapies in both human and mouse
CLL cells with or without p53 deficiency. To determine the effect of p53
deficiency on CLL treatment response on animal level, 20 TCL1-Tg:p53-/- mice
will be treated with nano-PEITC weekly through iv injection. Another 20 TCL1Tg:p53-/- mice will be treated with NL-101 2 times/month through iv injection.
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We expect that both PEITC and NL101 will prolong the survival time of TCL1Tg:p53-/- mice.
In summary, the major objective of the proposed researches is to establish a
CLL mouse model with p53 deficiency. This TCL1-Tg:p53-/- mouse model will
be utilized for testing novel therapeutic strategies and studying the effect of p53
deficiency on CLL biology and pathogenesis. These proposed studies will
provide new insights into how p53 deficiency affects expression of some
specific miRNAs and their regulatory functions.
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Figure 1. Generation of TCL1-Tg:p53-/- mice. TCL1-Tg homozygous mice are
crossed with p53-/- mice. Then the second generation of TCL1-Tg:p53+/- mice
are intercrossed to get TCL1-Tg:p53-/- mice, TCL1-Tg:p53+/- mice, TCL1Tg:p53wt mice and non-TCL1-Tg mice.
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3. MATERIAL AND METHODS
3.1 Generation of TCL1-Tg:p53-/- mice. TCL1-Tg mice (B6C3) were
kindly provided by Dr. Carlo M. Croce. They were crossed with p53-/- mice
(B6C3) which were from Jennifer Alana (a microinjection specialist in MD
Anderson Cancer Center). Then the second generation of TCL1-Tg:p53+/- mice
were intercrossed to get TCL1-Tg:p53-/- CLL mouse model. For research
studies, pure TCL1-Tg:p53-/- mice were obtained by intercrossing TCL1-Tg:p53/-

mice (Figure 1). All mice were housed under conventional barrier protection

in accordance with University of Texas MD Anderson Cancer Center guidelines,
and mouse protocols were approved by the University of Texas MD Anderson
Cancer Center Institutional Animal Care Committee. Survival data were
obtained by observing mice up to 2 years (n=33 for TCL1-Tg:p53-/- mice and
n=20 for TCL1-Tg mice). For mouse genotyping, small segments of mouse tail
tips were collected from littermates at the age of 3-4 weeks, and were digested
in 200 µL direct PCR lysis reagent with 5 µL proteinase K at 56ºC in a water
bath for overnight, followed by a 5-minute incubation at 95ºC and then cooled
on ice. After removal of tissue debris by centrifugation, 2 µL supernatant was
used in a PCR reaction for genotyping. All primers were purchased from Sigma.
3.2 Blood smear. Around 250 µL blood/mouse was collected from mouse
tail of 5 mice for each genotype and put in an EDTA-coated tube. All blood
samples were mixed well upon collection. Complete Blood Count (CBC)
service and WBC differential count service were provided by Department of
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Veterinary Medicine & Surgery Section of Veterinary Laboratory Medicine in
MD Anderson Cancer Center.
3.3 Histopathology. Mouse spleen, liver and lymph node tissues from 6
mice of each type were fixed in neutral buffered 10% formalin solution. After
24h, the tissues were transferred to 70% alcohol. Within 3 months after fixation
in 70% alcohol, the fixed tissues were sent to the histology core laboratory in
MD Anderson Cancer Center for preparing histology slides. Extra sections of
the tissues were embedded in paraffin. Sections were stained with hematoxylin
and eosin (H&E) or Ki67 by the histology core laboratory in MD Anderson
Cancer Center. H&E stained tissue slides were analyzed by Dr. Hesham M.
Amin from the department of hematopathology in MD Anderson Cancer Center.
3.4 Polymerase Chain Reaction (PCR). For mouse genotyping, TCL1
and p53 DNA contents were amplified using their specific primers. The TCL1
DNA amplifying protocol was provided by Dr. Croce’s group. Primers for
TCL1

are:

sense,

5’GCCGAGTGCCCGACACTC3’

and

antisense,

5’CATCTGGCAGCAGCTCGA3’ The PCR using TCL1 primers was
conducted at 94°C for 5 min for an initial denaturation step followed by 30
cycles for 30 sec of denaturation at 94°C, 30 sec of annealing at 65°C, and 30
sec of extension at 72°C, and a final extension step of 7 min at 72°C. The p53
DNA amplifying protocol was provided by Chad Smith (Transgenic Core
Facility of MD Anderson Cancer Center).

Primers for p53 are: p53-X7,

5’GGATGGTGGTATACTCAGAGCC3’,
5’AGCGTGGTGGTACCTTATGAGC3’

p53-X6,
and

neo19,
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5’GCTATCAGGACATAGCGTTGGC3’. The PCR for amplifying p53 was
performed at 95°C for 5 min for an initial denaturation process followed by 35
cycles for 1 min of denaturation at 95°C, 1min of annealing at 60-62°C, and 3
min of extension at 72°C, and a final extension step of 7 min at 72°C. The PCR
results are ready for DNA gel electrophoresis or saved at -20°C. 1.8% agarose
gel was prepared for electrophoresis. After DNA gel electrophoresis, the PCR
results were separated on agarose gel and visualized on alpha-imager.
3.5 Isolation of CLL cells and cytotoxicity assays. Primary leukemia
cells were isolated from the peripheral blood samples of CLL patients
diagnosed according to the NCI criteria (112). Proper informed consents under
a research protocol approved by the Institutional Review Board (IRB) of MD
Anderson Cancer Center were obtained from all patients before the collection of
blood samples. Specimens from CLL patients with or without 17p deletion
were all used for comparison. CLL cells were isolated from blood samples by
density gradient centrifugation as described previously (45), and incubated in
RPMI 1640 medium supplemented with 10% FBS and Penicillin (100 U/ml) +
Streptomycin (100 ug/ml) overnight before testing drug sensitivity by
incubation with CLL chemotherapies such as fludarabine. PC cells and
splenocytes were isolated and treated with ACK cell lysis buffer for 2 minutes
on ice to remove red blood cells. After lysis, RPMI medium with 10% FBS was
added to the cells to stop the lysis. Afterwards, the cells were washed once by
PBS and filtered through cell strainer with 40 µM nylon mesh (Fisher Scientific,
Pittsburgh, PA) for single cell preparation and cultured in the same medium as
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human CLL cells. B cells were purified from CLL cells by using CD19
microbeads, and incubated in RPMI 1640 medium supplemented with 10% FBS
and Penicillin (100 U/ml) + Streptomycin (100 ug/ml). At the same day, those B
cells were treated with fludarabine or oxaliplatin for 48h.

Cell viability and

cellular sensitivity to drug treatment in vitro were determined by flow
cytometry after double staining of 1x106 cells with annexinV-fluorescein
isothiocyanate (FITC) and PI analysis.
3.6 Reagents. 9--D-arabinofuranosyl-2-fluoro-adenine (F-ara-A, the
nucleoside form of fludarabine), oxaliplatin, SAHA, PEITC, chlorambucil, 3DZNep, PI and PCR primers were purchased from Sigma-Aldrich (St. Louis,
MO). Direct PCR lysis reagent was purchased from Viagen Biotech Inc. (Los
Angeles, CA). ACK lysis buffer was from Lonza Houston, Inc. (Houston, TX).
Ficoll-lite Lympho H (Fico) was from Atlanta Biological (Lawrenceville, GA).
CD19 microbeads were purchased from MACS Miltenyi Biotech Inc. (Auburn,
CA). Annexin V-FITC was from BD Biosciences (San Jose, CA). NL-101
compound was from Northlake Biosciences LLC (Lexington, MA). TUNEL
staining kit was obtained from Roche Applied Science (Indianapolis, IN).
Antibodies against Bcl-XL, Bcl-2, EZH2 and-actin were purchased from Cell
Signaling Technology Inc. (Danvers, MA). Anti-b-Myb antibody was from
EMD Millipore (Billerica, MA). Anti-Mcl1 antibody was from Santa Cruz
Biotechnology (Santa Cruz, CA).
3.7 Reverse Transcription Polymerase Chain Reaction (RT-PCR).
Total RNA from 1X107 splenocytes isolated from TCL1-Tg, TCL1-Tg:p53+/-
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and TCL1-Tg:p53-/- mice (4 for each genotype), were extracted, purified
( RNeasy Mini kit, Qiagen) and quatified by Ultrospec 3300 pro UV/visible
spectrophotometer. First-strand cDNA was synthesized from 0.5 µg total RNA
by using a commercial kit (RevertAid First Strand cDNA Synthesis KitFermentas) according to the manufacturer’ instructions. Real-time PCR was
performed with 7900 GT Sequence Detection System (ABI PRISM). All human
and mouse primers for Bcl-XL, Mcl-1, Bcl-2, EZH2, b-Myb and CXCL12 were
purchased from Sigma. Each PCR was performed in a 25-µL volume on a 96well optical plate for 2 minutes at 50ºC, followed by 10 minutes at 95ºC, then
followed by 40 cycles of 95ºC for 30 seconds, 60ºC for 30 seconds and 72ºC for
1minute and followed by 10 minutes at 72ºC. To independently validate the
individual miRNA expression pattern from the miRNA array result, total RNA
was isolated from patient white blood cells, and spleen cells from TCL1-Tg,
TCL1-Tg:p53+/-

and TCL1-Tg:p53-/- mice by using miRNA isolation kit

(Ambion). Then cDNA synthesis was carried out using Taqman MiRNA
Reverse Transcription kit and specific Taqman RT primers (Applied
Biosystems). MiRNA-specific real-time PCRs were performed using Taqman
Universal PCR Master Mix and Taqman small assays according to the
manufacturer’s protocol. The relative expression of specific miRNAs was
calculated by the delta (deltaCt) method.
3.8 Immunoblotting. Primary CLL cells were isolated from patient blood
using Fico as described above. Mouse splenocytes and PC cells were purified
by ACK lysis buffer. B cells were purified by CD19 microbeads. Cell number
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was determined by a Coulter Z2 particle count and size analyzer (Beckman
Coulter, Inc., Fullerton, CA). The mouse splenocytes/PC cells or human CLL
cells /B cells with same amount were then lysed in protein lysis buffer
containing a cocktail of protease inhibitors. The nuclei and cell debris were
removed by centrifugation at 4°C (13,000 rpm for 5 min), and the supernatants
were collected as protein lysates. The protein lysates were then heated at 95°C
for 5-15 min and separated by SDS-PAGE followed by Western blot analyses
with antibodies specific for Bcl-XL, Mcl-1, Bcl-2, EZH2 and B-Myb.
3.9 Flow cytometry. Single-cell suspensions were made from mouse
spleen, bone marrow and PC as described above, and stained for surface
expression with FITC-labeled anti-IgM, allophycocyanin (APC)-labeled antiCD5 antibodies (Ebioscience, San Diego, CA). Annexin V and propidium
iodide (PI) were used to monitor cell death.
3.10 Cell lines and cell culture. Stromal cell lines including human
stromal cell lines NKTert & HS5 and mouse stromal cell line Kusa.H1, EBVB
and Raji were cultured in RPMI 1640 medium supplemented with 10% FBS.
Human white blood cells were isolated from CLL patients’ blood using Fico
and cultured in RPMI 1640 medium supplemented with 10% FBS and Penicillin
(100 U/ml) + Streptomycin (100 ug/ml) (PS). Mouse splenocytes were cultured
in the same medium as used for human CLL cells. If co-culture applied, human
CLL cells and mouse splenocytes were co-cultured with appropriate amount of
stromal cells in 24-well plates one day before treatment with chemotherapies.
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3.11 Analysis of cell proliferation and apoptosis. Mouse spleen sections
were fixed in neutral buffered 10% formalin solution for 24h and then incubated
in 70% alcohol. The fixed tissues were sent to the histology core laboratory in
MD Anderson Cancer Center for preparing histology slides. Cell proliferation
was estimated by Ki67 immunostaining using Ki67 specific antibody and a
horseradish peroxidast (HRP)-conjugated secondary antibody to reveal the
diaminobenzidine (DAB) staining (Ki67 staining service ordered from the
histology lab in MD Anderson Cancer Center). Terminal deoxynucleotidyl
transferase deoxyuridine-triphosphatase nick-end labeling (TUNEL) assays
were performed with an In Situ Cell Death Detection kit (Roche Applied
Science, Indianapolis, IN) according to manufacturer’s instruction and
visualized under fluorescent microscopy. Annexin-V/PI double-staining and
flow cytometry analysis were used to monitor cell death.
3.12 Enzyme-linked immunosorbent assay (ELISA). SDF-1α (CXCL12)
ELISA kit was purchased from Fisher Scientific (Pittsburgh, PA). CXCL12
levels in drug treated NKTert, Kusa.H1 and HS5 stromal cells were determined
by ELISA assay according to manufacturer’s instruction.
3.13 Comet assay. 5X106 human CLL cells were treated with 3µM SAHA,
3µM NL-101, 10µM bendamustine and 3µM SAHA+10µM bendamustine for
24h. The cells were collected and mixed with 37°C Low Melting Poit (LMP)
agarose in dark. Then the cells were placed onto slides with coverslip for 5 min.
The slides were put into cold, freshly made lysing solution at 4°C for at least 1h.
The slides were gently removed from the lysing solution and briefly rinsed with
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neutralization buffer, and put in alkaline butter for 15 min in dark to allow for
unwinding of the DNA and expression of alkali-labile damage. Electrophoresis
was performed for the slides at 25v/300mA for 20 min. After electrophoresis,
the slides were dropwisely added neutralization buffer for 5 min and drained,
and coated with cold 100% ethanol and allowed drying. The dry slides were
stained with SYBR green and visualized under the fluorescent microscope.
Those slides were rinsed in 100% ethanol and stored after drying.
3.14 Statistical analysis. Student t tests were used for testing the statistical
difference between two groups of samples. Mouse survival curves by KaplanMeier plots were generated by Graphpad Prism software (GraphPad, San Diego,
CA), and the statistical significance was analyzed by the log-rank (Mantel-Cox)
test. A p value of less than 0.05 was considered statistically significant.

4. RESULTS
4.1 TCL1-Tg:p53-/- mice develop aggressive CLL with early disease
onset and short lifespan. P53 is one of the most frequently mutated genes in
cancers (22). In human B-CLL, loss of p53 function has been associated with
accelerated disease progression, poor prognosis, and resistance to antitumor
agents (17, 113). Currently there is no CLL mouse model with loss of p53 for
investigating the pathological process of this aggressive CLL. To create such a
animal model, we used the well-characterized TCL1 Transgenic CLL mice with
p53wt to cross breed with p53-/- mice to generate progenies harboring TCL1Tg:p53-/- genotype. Figure 2A shows the weights of spleens from 5 TCL1-
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Tg:p53wt (TCL1-Tg) and 5 TCL1-Tg:p53-/- mice. 17 mice in total 20 TCL1Tg:p53-/-

mice developed CLL with early disease onset at the age of

approximately 3 month, with severe splenomegaly by 4-5 month (Fig 4B). In
contrast, the spleens of TCL1-Tg mice with wt p53 or p53+/- mice appeared
relatively normal in size (Fig 2B). Histological examination of the spleen
sections of 4-month old TCL1-Tg mice showed normal tissue architecture,
whereas the histological sections of the spleen from 4-month TCL1-Tg:p53-/mice showed that the lymphoid follicles were ill-defined (Fig 2C).

The

germinal centers of the TCL1-Tg:p53-/- spleen exhibited histological features
reminiscent of the proliferation centers characteristic of CLL/small lymphocytic
lymphoma because of the presence of large lymphocytes with abundant
eosinophilic cytoplasm. The red pulps in between the lymphoid follicles
contained lymphoid cells with more abundant cytoplasm, granulocytes, and
megakaryocytes compared with red pulps seen in TCL1-Tg mouse spleen
(Figure 2C). Furthermore, blood smears revealed significant expansion of the
white blood cells (WBC) in TCL1-Tg:p53-/- mice compared to TCL1-Tg mice
(Figure 2D). Most of TCL1-Tg:p53-/- mice died at the age of 3-5 months, while
the most of the TCL1-Tg mice survive more than 12 months (Fig 2E). This was
consistent with the clinical observations that CLL patients with 17p deletion
have significantly shorter overall survival compared to the CLL patients without
17p deletion (56).
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Figure 2. Characterization of CLL phenotype of TCL1-Tg:p53-/- mice. (A)
Spleen weights shown for age- and sex-matched TCL1-Tg and TCL1-Tg:p53-/mice at 4 months (n=5 per indicated genotype). **, p<0.01 between group. (B)
Spleen size shown for age- and sex-matched WT, TCL1-Tg, TCL1-Tg:p53+/and TCL1-Tg:p53-/- mice at 4 months and 5 months old of age (1. WT; 2. TCL1Tg; 3. TCL1-Tg:p53+/-; 4. TCL1-Tg:p53-/-). Almost 100% TCL1-Tg:p53-/- mice
older than 4 months had larger spleen compared to that of TCL1-Tg mice. (n=20
per indicated strain).
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Figure 2C. Hematoxylin-eosin (H&E) staining. H&E staining of the spleen
from TCL1-Tg and TCL1-Tg:p53-/- mice at 4-month of age. Mouse spleen
tissues were fixed in 10% formalin buffered solution and embedded in paraffin.
Tissue section from a representative 4-month TCL1-Tg mouse showed normal
architecture (top panels), while the spleen from a representative TCL1-Tg:p53-/mouse showed ill-defined lymphoid follicles (bottom panels) (n=6 per indicated
strain).
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Figure 2D
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Figure 2D. White blood cells (WBC) count. Around 250 µL blood/mouse was
collected from mouse tail of 5 mice for each genotype and put in an EDTAcoated tube. All blood samples were mixed well upon collection. Complete
Blood Count (CBC) service and WBC differential count service were provided
by Department of Veterinary Medicine & Surgery Section of Veterinary
Laboratory Medicine in MD Anderson Cancer Center. WBC count in the
indicated mouse strains at different ages (n=5 per indicated age). *, p<0.05
between groups.
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Figure 2E
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Figure 2E. Survival curve (Kaplan-Meier) of TCL1-Tg (n=20) and TCL1Tg:p53-/- mice (n=33). Median survival time for the TCL1-Tg:p53-/- mice was
3.8 months compared to 19 months for TCL1-Tg mice (p<0.01).
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Since TCL1-Tg mice show features of human CLL with an increase in
CD5+/IgM+ B cells in PC, spleen and bone marrow (60), we compared
CD5+/IgM+ cells in the PC, spleen, and bone marrow of the wild-type mice,
TCL1-Tg mice, TCL1-Tg:p53+/- mice, and TCL1-Tg:p53-/- mice.

Flow

cytometry analysis showed that at the age of 4 months, the wild-type mice
showed 8% CD5+/IgM+ cells in the PC, the TCL1-Tg mice had 21% CD5+/IgM+
cells, and the TCL1-Tg:p53+/- and TCL1-Tg:p53-/- mice had 35% and 41%
CD5+/IgM+ cells in the PC, respectively (Figure 3A).

By 5 months, the

CD5+/IgM+ cells in the PC of TCL1-Tg:p53+/- and TCL1-Tg:p53-/- mice
increased to 58% and 79%, respectively (Figure 3B). In the spleens of a 5month old mice, the CD5+/IgM+ cells were undetectable in the wild-type mice,
7% in TCL1-Tg mice, 15% in TCL1-Tg:p53+/- mice, and 20% in TCL1-Tg:p53-/mice (Figure 3C). These data seemed consistent with the early onset of CLL in
TCL1-Tg:p53-/- mice (Figure 2). At 3-5 months, no CD5+/IgM+ cells were
detected in bone marrow of those mice. No such CD5+/IgM+ CLL population
was observed in bone marrow of 7-month old TCL1-Tg:p53+/- mice (Figure 3D).
In the spleens of 4-month old p53-/- mice, the CD5+/IgM+ cells were
undetectable, and only about 10% CD5+/IgM+ cells were observed in the PC of
those mice (Figure 3E).
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Figure 3. TCL1-Tg:p53-/- mice had early onset of leukemia and increased
CD5+/IgM+ B cells compared to TCL1-Tg mice. PC cells and splenocytes were
isolated and treated with ACK cell lysis buffer for 2 minutes on ice to remove red
blood cells. After lysis, RPMI medium with 10% FBS was added to the cells to

stop the lysis. Afterwards, the cells were washed once by PBS and filtered
through cell strainer with 40 µM nylon mesh for single cell preparation. (A)
Flow cytometry analysis (FITC-IgM/APC-CD5 staining) of PC cells from sexmatched different mouse strains collected at 4-month old of age (n=4 per
indicated genotype), and quantitative bar graph shown on the right panel. (B)
Flow cytometry analysis (FITC-IgM/APC-CD5 staining) of PC cells from sexmatched different mouse strains collected at 5-month old of age (n=4 per
indicated genotype), and quantitative bar graph shown on the right panel. (C)
Flow cytometry analysis (FITC-IgM/APC-CD5 staining) of splenocytes from
sex-matched different mouse strains collected at 5-month old of age (n=4 per
indicated genotype), and quantitative bar graph shown on the right panel.

42

Figure 3D
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Figure 3D. Flow cytometry analysis (FITC-IgM/APC-CD5 staining) of
bone marrow cells from sex-matched different mouse strains collected at 7month old of age (n=4 per indicated genotype), and quantitative bar graph
shown on the right panel. **, p<0.01 between groups. Bone marrow cells
were isolated from mouse legs and washed once by PBS and filtered through
cell strainer with 40 µM nylon mesh for single cell preparation.
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Figure 3E
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Figure 3E. Flow cytometry analysis (FITC-IgM/APC-CD5 staining) of
splenocytes and PC cells from 3 p53-/- mice at 4-month old of age. PC cells
and splenocytes were isolated and treated with ACK cell lysis buffer for 2 minutes on
ice to remove red blood cells. After lysis, RPMI medium with 10% FBS was

added to the cells to stop the lysis. Afterwards, the cells were washed once by
PBS and filtered through cell strainer with 40 µM nylon mesh for single cell
preparation.
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4.2 Loss of p53 in CLL cells promotes proliferation and cell survival.
Recent study suggested that CLL cells in TCL1-Tg mice may undergo
accelerated cell proliferation accompanied by elevated cell apoptosis, thereby
displayed a low accumulation of CLL cells and slow disease progression (70).
Since p53 plays a pivotal role in regulation of cell proliferation and apoptosis in
response to various stimuli, we examined if a loss of p53 might affect CLL cells
proliferation in TCL1-Tg mice. Immunostaining of spleen tissue slides with the
proliferation marker Ki-67 revealed that Ki67-positive cells were significantly
higher in the spleens of TCL1-Tg:p53-/- mice compared to that of TCL1-Tg mice
(Figure 4A, 4C), suggesting an increase in proliferation of the splenocytes in
TCL1-Tg:p53-/- mice. We then used TUNEL assay to compare in vivo apoptosis
of splenocytes in TCL1-Tg and TCL1-Tg:p53-/- mice. TUNEL staining of the
spleen tissue sections showed that TCL1-Tg:p53-/- mice had significantly less
apoptotic cells in the spleen compared to that in the spleen of TCL1-Tg mice
(Figure 4B, 4D). Consistently, annexin-V/PI double-staining of the splenocytes
revealed that the isolated splenocytes from TCL1-Tg:p53-/- mice were less
apoptotic when cultured in vitro for 24-72 h compared to the splenocytes
isolated from TCL1-Tg mice culture under identical conditions (data not shown).
Taken together, these data suggest that the loss of p53 in TCL1-Tg mice seems
to promote cell proliferation and decrease apoptosis. This might account for the
much higher accumulation of CLL cells and rapid disease progression in TCL1Tg:p53-/- mice.
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Figure 4A-4D
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Figure 4. P53 deficiency increased cell proliferation and elevated cell
survival of leukemia cells from TCL1-Tg:p53-/- mice. (A) Mouse splenic
sections were stained with the proliferation marker Ki-67 for age and sexmatched TCL1-Tg and TCL1-Tg:p53-/- mice. (B) Left panel, apoptosis in splenic
sections shown by staining with TUNEL-TMR-Red. Right panel, DAPI staining
indicates nuclear staining of total cells. (C) Statistic analysis of the results for A
showed average of Ki67-positive cells/field from splenic sections, respectively
(n=3 per group). *, p<0.05, **, p<0.01 between groups. (D) Statistic analysis of
the results for B showed average of TUENL-positive cells/field from splenic
sections, respectively (n=3 per group). *, p<0.05, **, p<0.01 between groups.
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4.3 Leukemia cells from TCL1-Tg:p53-/- mice or from CLL patients
with 17p deletion are resistant to chemotherapeutic drugs. The observations
that the leukemia cells isolated from TCL1-Tg:p53-/- mice exhibited less
spontaneous apoptosis (Fig 4B, 4D) prompted us to speculate that the leukemia
cells with loss of p53 might be less sensitive to apoptotic induction and thus
might be more resistant to chemotherapeutic agents. To test this possibility, we
isolated splenocytes from the wild-type control mice and from TCL1-Tg, TCL1Tg:p53+/- and TCL1-Tg:p53-/- mice, and then treated the cells with several
standard anti-CLL chemotherapeutic agents in culture (114). As shown in
Figure 5, the splenocytes from the control and TCL1-Tg mice exhibited similar
sensitivity to F-ara-A (active form of fludarabine, 10 M), chlorambucil (10
M), and oxaliplatin (10 M). The loss of one p53 allele (TCL1-Tg:p53+/-)
caused a moderate decrease in drug sensitivity, whereas the loss of both p53
alleles (TCL1-Tg:p53-/-) led to a significant resistance to all three
chemotherapeutic agents (Figure 5).
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Figure 5

51

Figure 5. P53 deletion makes mouse leukemia cells more resistant to
standard CLL drug treatment. Splenic cells from indicated mouse strains
were cultured in RPMI1640 medium with 10% FBS plus 1% PS and treated
with 10uM F-ara-A, Chlorambucil and Oxaliplatin for 48h, and Annexin V-PI
analysis by FACS was performed to detect apoptosis on those splenocytes (n=4
per group).
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To further confirm the correlation between the loss of p53 and drug
resistance in primary CLL cells from patients, we compared the drug sensitivity
of primary leukemia cells from CLL patients with or without 17p deletion.
Flow cytometry analysis showed that CLL cells isolated from patients without
17p deletion were sensitive to F-ara-A (10µM) and oxaliplatin (10µM), which
caused a loss of 40-50% cell viability during the 48-h drug incubation (Figure
6). For instance, in patient #1 the control cell showed 78% viability, and drug
treatment led to a substantial decrease of viable cells (37-41%). Similar results
were observed in CLL cells from patient #2. In contrast, CLL cells with 17p
deletion were highly resistant to F-ara-A and oxaliplatin (Figure 6, patients #3
& #4). For instance, in CLL sample #4, the control sample without drug
treatment showed 87% viable cells. After treatment with F-ara-A or oxaliplatin,
the cell viability remained at 85-86%. Similar drug resistance was observed in
patient sample #3. Treatment resistance was also observed in other patient
samples with 17p deletion (patients #8 to #10) as shown in Figure 7. The Figure
8 showed similar drug resistance of 17p- B cells isolated from primary CLL
cells. The results from experiments with leukemia cells from mice and from
CLL patients consistently suggest that the loss of p53 leads to the drug
resistance to standard chemotherapeutic drugs.
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Figure 6. P53 deletion makes human leukemia cells more resistant to
standard CLL drug treatment. White blood cells were isolated from CLL
patients’ blood and cultured in RPMI1640 medium containing 10% FBS and
1% PS. CLL patient samples with 17p WT (Pt #1 & Pt #2) or with >70% 17p
deletion (Pt #3 & Pt #4) were treated with 10uM F-ara-A and 10uM Oxaliplatin
for 48h, respectively. Cell apoptosis was analyzed by Annexin V-PI double
staining.
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Figure 7
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Figure 7. For more patient samples, p53 deletion makes leukemia cells
more resistant to standard CLL drug treatment. CLL patient samples with
17p WT (Pt #5-7) or with 17p deletion (Pt #8-10) were treated with 10uM Fara-A and 10uM Oxaliplatin for 48h, respectively. Cell apoptosis was analyzed
by Annexin V-PI double staining.
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Figure 8
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Figure 8. P53 deletion makes human leukemia B cells more resistant to standard
CLL drug treatment. White blood cells were isolated from CLL patients’ blood and
cultured in RPMI1640 medium containing 10% FBS and 1% PS. CD19 positive B cells
purified from CLL patient samples with 17p WT (Pt A-C) or with 17p deletion (Pt D-F).
After purification, B cells were treated with 10uM F-ara-A and 10uM Oxaliplatin for
48h, respectively. Cell apoptosis was analyzed by Annexin V-PI double staining.
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4.4 Loss of p53 in CLL cells promotes Mcl-1 expression associated
with down-regulation of miR-15a and miR-16-1. To investigate the
mechanisms that contribute to the drug resistant phenotype in CLL cells lacking
p53, we first compared the expression of the anti-apoptotic Bcl-2 family
members including Bcl-2, Mcl-1, and Bcl-XL in CLL cells isolated from the
spleens and PCs of the TCL1-Tg and TCL1-Tg:p53-/- mice.

Western blot

analysis showed that the expression of these anti-apoptotic molecules increased
to various degrees in the p53-null cells (Figure 9A), with the elevation of Mcl-1
protein being the most prominent event, which was detected in leukemia cells
isolated from spleen and PC. Bcl-XL protein levels were also increased in both
the splenocytes and PC cells from TCL1-Tg:p53-/- mice compared to TCL1-Tg
mice.

Interestingly, the increased Bcl-2 was observed in the peritoneal

leukemia cells but not in splenocytes (Figure 9A). Real-time RT-PCR analysis
showed a significant increase in mRNA expression of Mcl-1, Bcl-XL, and Bcl-2
in the splenocytes and PC cells from TCL1-Tg:p53-/- mice compared to those
from TCL1-Tg mice (Figures 9B-9D). Importantly, the increase in Mcl-1, BclXL, and Bcl-2 protein expression was also observed in primary CLL cells
isolated from patients with 17p deletion (Figure 10A). Such increase was
consistently observed in multiple patient samples. Real-time RT-PCR analysis
showed that the mRNA expression of these 3 molecules was also increased in
CLL cells with 17p deletion (Fig 10B). These data together suggest that the
increased expression of Bcl-2 family members occurred mainly at
transcriptional level. Consistently, both protein and mRNA levels of Mcl-1 and
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Bcl-XL were increased in 17p- B cells isolated from patient CLL cells (Figure
11 & Figures 12A-12B). Interestingly, the increased Bcl-2 expression was
observed in 17p- B cells from part of patient samples (Fig 11 & Fig 12C).
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Figure 9. Bcl-2 survival family gene expression in mouse splenocytes and
PC cells isolated from TCL1-Tg and TCL1-Tg:p53-/- mice. (A) Mcl-1, BclXL and Bcl-2 protein expression shown by Western blot analysis. (splenocytes
were isolated from 4-month old mice; n=4 per group ).
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Figure 9. Bcl-2 survival gene expression in cells from TCL1-Tg and TCL1Tg:p53-/- mice. (B) Mcl-1 mRNA levels in mouse splenocytes and PC cells
shown by RT-PCR (n=4 per indicated strain). *, p<0.05, **, p<0.01 between
groups. (C) Bcl-XL mRNA levels in mouse splenocytes and PC cells shown by
RT-PCR (n=4 per indicated strain). *, p<0.05, **, p<0.01 between groups. (D)
Bcl-2 mRNA levels in mouse splenocytes and PC cells shown by RT-PCR (n=4
per indicated strain). *, p<0.05, **, p<0.01 between groups.
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Figure 10A-10B
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Figure 10. Bcl-2 survival family gene expression in CLL cells from human
patient samples with 17p deletion or with 17p wt. (A) Western blot analysis
showed Mcl-1, Bcl-XL and Bcl-2 protein levels in CLL cells from human CLL
patient samples with or without 17p deletion (4 >70% 17p deletion samples:
del1-4; 6 17p WT samples: WT1-6). (B) Mcl-1, Bcl-XL and Bcl-2 mRNA
levels in CLL cells from human patients with or without 17p deletion shown by
RT-PCR. *, p<0.05, **, p<0.01 between groups.

67

Figure 11

B cells /17p: wt wt wt del del del del
Mcl-1
Bcl-XL
Bcl-2
β-actin

68

Figure 11. Bcl-2 survival family gene expression in CLL-B cells from
patient samples with 17p deletion or with 17p wt. Western blot analysis
showed Mcl-1, Bcl-XL and Bcl-2 protein levels in CD19 positive B cells from
human CLL patient samples with or without 17p deletion (3 17p WT samples
and 4 17p- samples).
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Figure 12. mRNA levels of Bcl-2 survival family in CLL-B cells from
patient samples with 17p deletion or with 17p wt. (A) Mcl-1 mRNA levels in
CD19 positive B cells from human CLL patient samples with or without 17p
deletion (3 17p WT samples and 4 17p- samples). (B) Bcl-XL mRNA levels in
CD19 positive B cells from human CLL patients with or without 17p deletion (3
17p WT samples and 4 17p- samples). (C) Bcl-2 mRNA levels in CD19 positive
B cells from human CLL patients with or without 17p deletion (3 17p WT
samples and 4 17p- samples).
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To further investigate the possible mechanisms by which loss of p53 led
to increased expression of multiple Bcl-2 family members, we speculated that
since the expression of Bcl-2 multiple family members is known to be regulated
by certain microRNAs (miR15a, miR-16) (115), it is possible that the loss of
p53 might cause a decrease expression of some specific microRNAs, leading to
over-expression of Mcl-1, Bcl-XL, and Bcl-2. To test this possibility, we first
isolated total RNA from the splenocytes of TCL1-Tg and TCL1-Tg:p53-/- mice,
and explored the expression profiles of microRNAs.

Among the >300

microRNAs detected, miR-15a and miR-16-1 were markedly decreased in
TCL1-Tg:p53-/- mice compared to that of TCL1-Tg mice. The decrease of miR15a and miR-16-1 in cells from TCL1-Tg:p53-/- mice was further confirmed by
real-time RT-PCR using the leukemia cells isolated from the spleens and PCs of
TCL1-Tg and TCL1-Tg:p53-/- mice. As shown in Figure 13A, there was a
significant decrease in the expression of miR-15a and miR-16-1 in both
splenocytes and PC cells from mice without p53. Importantly, the decrease in
miR-15a/16 expression was further confirmed in primary CLL cells isolated
from patients with 17p deletion (Figure 13B).

Consistently, similar results

were observed in B cells isolated from primary CLL cells (Figure 14). These
data together suggest that suppression of miR15a/miR16-1 expression may be
an important mechanism by which the loss of p53 enhances the expression of
Mcl-1, Bcl-2 and Bcl-XL, leading to increased cell viability and drug resistance.
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Figure 13. Expression of tumor suppressor miR-15a/16-1 in mouse and
human leukemia cells. (A) MiR-15a/16-1 expression in mouse splenocytes and
PC cells shown by RT-PCR. *, p<0.05, **, p<0.01 between groups. (B) MiR15a/16-1 expression in CLL cells from patient samples with or without 17p
deletion shown by RT-PCR. *, p<0.05, **, p<0.01 between groups.
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Figure 14A-14B
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Figure 14. MiR15a/16-1 expression in CLL-B cells. (A) MiR-15a expression
in CD19 positive B cells purified from patient samples with or without 17p
deletion shown by RT-PCR (3 17p WT samples and 4 17p- samples). (B) MiR16-1 expression in CD19 positive B cells purified from patient samples with or
without 17p deletion shown by RT-PCR (3 17p WT samples and 4 17psamples).
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4.5 Loss of p53 in CLL cells causes down-regulation of miR-30 family,
leading to upregulation of downstream oncogenes EZH2 and B-Myb. In
addition, among the >300 microRNAs detected, miR-30a, miR-30e, and
particularly miR-30d were markedly decreased in TCL1-Tg:p53-/- mice
compared to that of TCL1-Tg mice. The downregulation of miR-30 family in
cells from TCL1-Tg:p53-/- mice was further confirmed by real-time RT-PCR
using the leukemia cells isolated from the spleens and PCs of TCL1-Tg and
TCL1-Tg:p53-/- mice. As shown in Figure 15A, there was a significant decrease
in the expression of miR-30 family in both splenocytes and PC cells from mice
without p53. Importantly, the decrease in miR-30 family expression was further
confirmed in primary CLL cells isolated from patients with 17p deletion (Figure
15B). It has been reported that miR-30d targets EZH2 which is involved in
repressing gene expression through methylation of histone H3 on lysine 27 and
upregulated in anaplastic thyroid carcinomas (90). Over years, many studies
have established that EZH2 is overexpressed in various cancers including some
hematologic malignancies, and such overexpression is associated with
aggressive disease progression (91, 92). The role of EZH2 in CLL has yet to be
examined in vitro and in vivo. Another target of miR-30 is B-Myb, which
expression can be regulated by miR-30 and miR-29 during cellular senescence
(95). B-Myb, a transcription factor, is involved in cell proliferation and
transcription and carcinogenesis. B-Myb overexpression presents in various
cancers and is associated with aggressive tumor growth and poor outcomes (9698). However, the role of B-Myb in CLL is still unknown. Both EZH2 and B-
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Myb are upregulated in mouse CLL cells with p53 deletion as shown in Figure
16. The EZH2 inhibitor 3-deazaneplanocin (DZNep) led to induction of more
apoptosis in splenocytes isolated from TCL1-Tg:p53-/- mice compared to that of
TCL1-Tg mice (Figure 17). Taking together, this study provides evidence to
support the important role of p53miR30dEZH2 & B-Myb axis in the
development of aggressive CLL.
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Figure 15. Expression of tumor suppressor miR-30 family in mouse and
human leukemia cells. (A) MiR-30a, miR-30d and miR-30e expression in
mouse splenocytes and PC cells shown by RT-PCR. *, p<0.05, **, p<0.01
between groups. (B) MiR-30a, miR-30d and miR-30e expression in CLL cells
from human patient samples with or without 17p deletion shown by RT-PCR. *,
p<0.05, **, p<0.01 between groups.
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Figure 16. Expression of EZH2 and B-Myb in mouse and human CLL
cells. (A) Expression of EZH2 and B-Myb in splenocytes from 3 TCL1-Tg mice,
3 TCL1-Tg:p53+/- mice, and 6 TCL1-Tg:p53-/- mice. (B) Expression of EZH2
and B-Myb in 7 human CLL samples with 17p wt and 6 CLL samples with 17p
deletion.
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Figure 17
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Figure 17. DZNep treatment in mouse splenocytes. Splenic cells from 3
TCL1-Tg and 3 TCL1-Tg:p53-/- mice were cultured in RPMI1640 medium with
10% FBS plus 1% PS and treated with 3uM SAHA, 3uM 3-DEZNP, 10uM Fara-A or their combination for 48h. PEITC treatment was only 4 h. Annexin VPI analysis by FACS was performed to detect apoptosis for those splenocytes.
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4.6 New compound NL-101 induces significant apoptosis in CLL cells
with or without p53 deficiency. Despite of the fact that various advanced
therapeutic strategies have improved the CLL treatment in clinic, the disease is
not cured yet. As shown in Figures 5-8, CLL cells with p53 deficiency were
resistant to conventional CLL chemotherapies such as F-ara-A. Therefore it is
urgent to study new therapeutic strategies for the treatment of the subtype of
CLL with p53 deficiency. It was observed that new compound NL-101 induced
significant apoptosis in CLL cell with 17p wt (Figure 18). NL-101 contains both
the HDACI-SAHA and the alkylating agent-Bendamustine moieties in 1:1 ratio.
48h treatment of 3µM NL-101 induced around 85% apoptosis in CLL cells
cocultured with NKTert cells. 48h treatment of 3µM SAHA only induced about
75% apoptosis in the CLL cells when cocultured with stromal cells NKTert.
However, 10µM Bendamustine didn’t induce any apoptosis in the CLL cells
cocultured with NKTert cells. The combination of 3µM SAHA + 10µM
Bendamustine almost killed all CLL cells even cocultured with NKTert cells.
Without coculture, those compounds only or their combination efficiently
induced apoptosis in the CLL cells (Figure 18A). The bar graph in Figure 18B
showed efficient killing effect of NL101 or SAHA combined with alkylating
agents in CLL cells with or without coculture with stromal cells. Interestingly,
NL-101 and PEITC both can induce significant apoptosis in CLL cells with 17p
deletion (Figure 19). As mentioned before, a subtype of CLL with chromosome
17p deletion is associated with accelerated disease progression, drug resistance,
and poor prognosis due to loss of p53 gene (100). In our studies, we observed
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that 4h 10µM PEITC treatment or 48h 6µM NL-101 treatment only induced
significant apoptosis in the subtype of CLL cells with 17p deletion with or
without coculture with stromal NKTert cells. Similarly SAHA combined with
Chlorambucil or Bendamustine also induced significant apoptosis in this
subtype of CLL with or without coculture with stromal NKTert cells. The NL101 compound combined with PEITC almost killed all of this subtype of CLL
cells as shown in Figure 21. Consistently the compound NL-101 also induced
significant apoptosis in mouse CLL cells when cocultured with stromal cells.
Interestingly not only NL-101 treatment but also SAHA treatment only induced
significant apoptosis in mouse splenocytes isolated from TCL1-Tg and TCL1Tg:p53-/- mice (Figure 20).
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Figure 18A-18B
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95

11

18

95
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Figure 18. NL-101 treatment in human CLL cells with 17p wt. White blood
cells were isolated from CLL patients’ blood and cultured in RPMI1640
medium containing 10% FBS and 1% PS. (A) CLL patient samples with 17p wt
were treated with 3uM NL-101, 3uM SAHA, 10uM Bendamustine and 3uM
SAHA+10uM Bendamustine for 48h when cocultured with human stromal cells
NKTert or without coculture. Cell apoptosis was analyzed by Annexin V-PI
staining. (B) The quantitative bar graph showed the treatment results analyzed
by Annexin V-PI staining in human CLL cells cocultured with stromal cells
NKTert or Kusa.H1 or without coculture.
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Figure 19
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Figure 19. NL-101, PEITC and other treatments in human CLL cells with
17p deletion 7. White blood cells were isolated from CLL patients’ blood and
cultured in RPMI1640 medium containing 10% FBS and 1% PS. CLL patient
samples with 17p deletion were treated with 3uM SAHA, 10uM Chlorambucil,
20uM Bendamustine, 10uM F-ara-A, 6uM or 10uM NL-101 and their
combinations for 48h with or without coculture with stromal NKTert cells.
10uM PEITC treatment was only 4h. Cell apoptosis was analyzed by Annexin
V-PI staining.
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Figure 20
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Figure 20. NL-101 treatment in mouse CLL cells with or without p53
deficiency. Splenic cells from TCL1-Tg and TCL1-Tg:p53-/- mice were cultured
in RPMI1640 medium with 10% FBS plus 1% PS and treated with 10uM F-araA or Chlorambucil, 20uM Bendamustine, 3uM SAHA or SAHA combined with
the alkylating agents and 3uM NL-101 for 48h when cocultured with stromal
Kusa.H1 cells. Annexin V-PI analysis by FACS was performed to detect
apoptosis for those splenocytes.
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4.7 NL-101 and PEITC treatment prolonged the survival time for
TCL1-Tg:p53-/- mice. Since we observed efficient killing effects of NL-101 and
PEITC in CLL cells with p53 deficiency in vitro, the NL-101 and PEITC
treatment in vivo were performed using intravenous injection (i.v. injection).
Tail inflammation was observed after 6 times of iv injection for some TCL1Tg:p53-/- mice. As shown in Figure 21, only 6 times i.v. injection of NL-101
prolonged the survival time of TCL1-Tg:p53-/- mice. PEITC treatment
significantly prolonged the survival time for the TCL1-Tg:p53-/- mice (Figure
21).
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Figure 21
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Figure 21. Survival curve (Kaplan-Meier) of TCL1-Tg:p53-/- mice treated
with NL-101 or PEITC (n=20 per group).

NL-101 treatment plan: 2

times/month i.v. injection of 6mg/ml for 3 months; PEITC treatment plan: i.v.
injection of Nano-PEITC weekly by 10mg/ml (1mg/10g weight) concentration.
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4.8 Underlying mechanisms of NL-101 induced apoptosis in CLL cells.
After observing significant killing effect of NL-101 in CLL cells, we
hypothesized that the HDACI-moiety of NL-101 can overcome resistance of the
alkylating agent-moiety in CLL treatment. More DNA strand breaks were
observed in CLL cells treated with NL-101 only or SAHA combined with
Bendamustine than Bendamustine treatment only analyzed by comet assay
(Figure 22). In addition, HDACI such as SAHA can overcome resistance of
alkylating agents in CLL treatment by reducing CXCL12 secreted from stromal
cells. RT-PCR experiments showed reduced levels of CXCL12 in stromal
NKTert cells treated with HDACI or NL-101 (Figure 23). In Figure 24, ELISA
assay showed significant decrease of CXCL12 levels in Kusa.H1 and NKTert
cells treated by HDACI such as SAHA and LBH. Interestingly the CXCL12
level was very low in stromal HS5 cells.
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Figure 22
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Figure 22. DNA strand breaks in CLL cells analyzed by Comet assay. CLL
cells were treated with 3µM SAHA, 3µM NL-101, 20µM Bendamustine or
3µM SAHA+20µM Bendamustine for 24h. The comet assay was performed as
described above.
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Figure 23
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Figure 23. CXCL12 mRNA levels in NKTert cells treated with HDACI,
HDACI combined with alkylating agents or NL-101 analyzed by RT-PCR.
1X105 NKTert cells were seeded in a 6-well plate. The HDACI or NL-101
treatment was performed when the cells were 70% confluent. 48h later, the cells
were collected and prepared for RNA isolation, cDNA synthesis and RT-PCR.
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Figure 24
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Figure 24. CXCL12 levels in stromal HS5, Kusa.H1 and NKTert cells
treated with SAHA or LBH determined by ELISA assay. 6X105 HS5 cells,
1X104 Kusa.H1 cells and 4X104 NKTert cells were seeded in 24-well plates
with RPMI1640 medium at day 1. At day 3, the medium was removed and
500µL fresh medium was added for each well. HDACI treatment was
performed at day 3. ELISA assay was performed at day 4.
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5. DISCUSSION
Recent progress in investigation of CLL biology and the development of
new therapies such as F-ara-A-based regimens has led to significant
improvements of therapeutic outcomes. However, many CLL patients,
particularly those with loss of p53 function due to chromosome 17p deletion
and p53 mutations, are refractory to the current therapeutic regimens with poor
prognosis (56). Loss of p53 function can be due to deletion or mutations of the
gene that encodes for p53, epigenetic silencing, and functional inactivation. In
CLL, chromosome 17p deletion and p53 mutations are well-documented
mechanisms that lead to loss of p53 function associated with poor prognosis (56,
116). The exact mechanisms by which loss of p53 may lead to aggressive
disease progression and poor clinical outcomes in CLL remain illusive. Based
on the important role of p53 in cell cycle control and regulation of apoptosis
(117), it is generally speculated that loss of p53 function may result in
impairment of cycle-cycle checkpoints and compromised apoptotic response,
leading to disease progression and drug resistance.

However, there is no

conclusive evidence in vivo to support this notion, perhaps in part due to the
lack of proper CLL animal model with loss of p53.
5.1 Rapid disease progression and treatment resistance
occurred in TCL1-Tg:p53-/- mice. In the present study, we generated a mouse
colony with TCL1-Tg:p53-/- genotype, and demonstrated that these mice
developed leukemia that resembles aggressive human CLL. The TCL1-Tg:p53/-

mice exhibited signs of CLL disease around 3 months, with early appearance
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of CD5+/IgM+ cells in the PC and spleen. Most TCL1-Tg:p53-/- mice showed
highly abnormal accumulation of WBC in the blood and developed severe
splenomegaly at 3-4 month, and died before 6 months. This is in contrast with
the TCL1-Tg mice, which develop CLL approximately at the age of 1 year, and
the disease progresses slowly (60). In the TCL1-Tg:p53-/- mice, we observed a
significant increase in lymphoid cell proliferation in the spleen and a decrease in
apoptosis.

This may explain why these mice had severe accumulation of

leukemia cells and enlargement of the spleen at early age. The control p53-/mice didn’t accumulate much leukemia cells at 4-month old of age, however,
our mouse model exhibited significant higher number of leukemia cells,
suggesting that TCL1-Tg:p53-/- mice had specific CLL features rather than
lymphoma occurring in p53-/- mice. Since p53 plays a key role in enhancing the
expression of apoptotic molecules such as Bax and PUMA (118), loss of p53
function would significantly compromise this apoptotic pathway, leading to
resistance to chemotherapeutic agents. In fact, we observed that the leukemia
cells isolated from TCL1-Tg:p53-/- mice or from CLL patients with 17p deletion
were highly resistance to standard anti-CLL drugs F-ara-A and oxaliplatin.
Furthermore, CD19 positive B cells purified from CLL patients with 17p
deletion were highly resistance to F-ara-A and oxaliplatin. To overcome
treatment resistance, new therapeutic strategies need to be applied in clinic such
as PEITC and NL-101 compound.
5.2 Up-regulated Mcl-1 in leukemia cells with p53 deletion. An
important observation in this study was the significant up-regulation of Mcl-1
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expression in the leukemia cells lacking p53.

This was seen both in the

leukemia cells from the TCL1-Tg:p53-/- mice and in primary CLL cells from
patients with 17p deletion (Figure 9 & 10).

Mcl-1 is a key anti-apoptotic

protein in the Bcl-2 family, and this molecule is known to be particularly
important for the survival of CLL cells (85). Thus, upregulation of Mcl-1 may
play a major role in apoptosis resistance in CLL cells lacking p53, and the
moderate increase in Bcl-XL and Bcl-2 expression may also contribute to the
increased viability of leukemia cells in TCL1-Tg:p53-/- mice. Since the increase
in Mcl-1 expression was observed at mRNA and protein levels, it is likely that
loss of p53 may promote Mcl-1 expression mainly at the transcriptional level.
This is consistent with the observation that p53 transcriptionally represses Mcl1 (119-122).
5.3 Down-regulated miR-15a/miR-16-1 in leukemia cells with p53
deletion. Interestingly, the miRNA expression levels of miR15a and miR-16-1
were significantly decreased in CLL cells with loss of p53. This was observed
both in the TCL1-Tg:p53-/- mouse model and in primary CLL cells isolated from
patients with 17p deletion. Because Mcl-1 is a target of miR-15a and miR-16-1
(123, 124), the decrease in these miRNAs would release their suppression on
Mcl-1 and thus lead to its elevated expression. Thus, it is possible that p53
might regulate Mcl-1 expression through modulating miR15a/16. It has been
shown previously that miRNAs may be involved in CLL pathogenesis and
prognosis due to their function as oncogenes or tumor suppressors (102). For
example, miR-15a/miR-16-1 is located in chromosome 13q14.3, a region that is
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frequently mutated or deleted in CLL patients and may affect CLL cell survival
and drug resistance (115). Intriguingly, p53 may regulate the expression of
multiple miRNAs, many of which are closely involved in cell cycle regulation,
proliferation and apoptosis (104). Our initial study using miRNA array to
examine the effect of loss of p53 on miRNA expression in the TCL1-Tg:p53-/mice had identified miR-15a and miR-16-1 being significantly down-regulated,
which was further validated by real-time RT-PCR. Clearly, miR-15a/16-1
expression is significantly lower in splenocytes and PC cells from TCL1Tg:p53-/- mice than that of TCL1-Tg mice. These observations together suggest
that p53miR-15a/16-1Mcl-1 axis may be an important pathway in
regulating CLL cell apoptosis and drug resistance. The important role of the
p53miR-15a/16-1Mcl-1 axis in the development of aggressive CLL merits
further investigation in clinical setting.
5.4 Down-regulated miR-30d in leukemia cells with p53 deletion.
Our initial study using miRNA array to examine the effect of loss of p53 on
miRNA expression in the TCL1-Tg:p53-/- mice had identified miR-30a, miR30e and particularly miR-30d being significantly down-regulated, which was
further validated by real-time RT-PCR. Clearly, miR-30a/miR-30d/miR-30e
levels were significantly lower in splenocytes and PC cells from TCL1-Tg:p53-/mice than that of TCL1-Tg mice. It has been reported that EZH2 and B-Myb are
targets of miR-30 family (90, 95). Since we observed significant up-regulation
of EZH2 and B-Myb in leukemia cells with p53 deletion, p53miR-
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miR30EZH2 & B-Myb axis may be another important pathway in regulating
CLL cell apoptosis and drug resistance.

6. SUMMARY AND CONCLUSIONS
The whole study can be summarized in the following diagram. I have
generated TCL1-Tg:p53-/- mice, which develop aggressive CLL with an early
disease onset, likely due to increase proliferation of the leukemia cells and
decrease in apoptosis. The CLL cells lacking p53 exhibited low sensitivity to
standard anti-CLL drugs. In our study, we tested new compound NL-101 and
PEITC in our mouse model. It has been reported that PEITC effectively
eliminates F-ara-A-resistant CLL cells through ROS accumulation and
glutathione depletion (45). We observed that PEITC was very efficient to
eliminate CLL cells both in vitro and in vivo. The underlying mechanism for
efficient killing effect of NL-101 in CLL is possible through HDAC inhibitorovercoming the treatment resistance of alkylating agents by inhibiting CXCL12
and inducing more DNA damage to CLL cells. Our study also provided in vivo
evidence that loss of p53 led to upregulation of Mcl-1 expression, probably
though the down regulation of miR-15a and miR-16-1 and thus released their
suppression

on

Mcl-1

expression.

Another

possibility

is

that

p53

transcriptionally represses Mcl-1, leading to decrease in apoptosis and drug
resistance in CLL cells from TCL1-Tg:p53-/- mice. Furthermore, loss of p53
cause down-regulation of miR-30 family especially miR-30d which regulates
up-regulation of EZH2 & B-Myb, probably leading to rapid disease progression
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and treatment resistance in leukemia cells lacking p53. The TCL1-Tg:p53-/mouse colony may serve as a valuable mouse model to further investigate the
pathogenesis of aggressive CLL due to loss of p53 function. In addition, since
these mice develop leukemia at early age and die within 6 months, this animal
model may be useful in testing new drugs for their in vivo therapeutic activity
against aggressive CLL with loss of p53 function.
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Summary

P53 deletion in TCL1-Tg mice

CLL development at early stage
with hyperproliferation, reduced
apoptosis, treatment resistance
and short survival time

PEITC, NL-101,…
Down-regulated MiR-15a/16-1

Up-regulated Mcl-1

Down-regulated miR-30d

Up-regulated oncogenes:
B-Myb, EZH2

Decreased apoptosis, increased proliferation, treatment resistance……
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